Hims’ Low-Cost GLP-1 Pill Intensifies Competition in the Fast- Growing Obesity Drug Market

Telehealth company Hims & Hers Shook The obesity- Drug market by introducing a low-cost compounded GLP-1 weight loss-pill, triggering sharp declines in Nova Nordisk and Eliu Lilly shares while rising regulatory and legal concerns.

Hims & Hers Health recently announced a compounded oral semaglutide pill designed as a lower- cost alternatives to branded GLP-1 weight-loss treatments, the product was launched at an introductory price of $ 49 per month, significantly below the prices of comparable branded therapies offered by Nova Nordisk and Eliu Lilly, the announcement immediately affected investor sentiment, with shares of both pharmaceutical giants declining as markets reacted to the possibility of increased pricing pressure in the obesity- treatment sector.

They moved quickly sparked controversy, Nova Nordisk argued that the compounded pill represented unauthorised copy of its newly launched oral weagovy project and threatened legal action, the company stated that compounded version are not FDA approved and me post concerns related to safety, efficacy, and quality, regulatory scrutiny intensified when the U.S. food and drug administration signaled potential enforcement action against mass- marketed compounded GLP-1 products, within days, Hims announced it would stop offering the pill following discussions with regulators and industries stakeholders.

According to Precedence Research, the global compounding pharmacy market size was calculated at USD 18.02 billion in 2025 and is predicted to increase from USD 19.19 billion in 2026 to approximately USD 33.63 billion by 2035, expanding at a CAGR of 6.44% from 2026 to 2035.

Advancing the Topic

This development highlights the growing demand for affordable obesity treatments, GLP-1 drugs have transformed weight- management therapy, but high prices remain a barrier for many patients, telehealth providers and compounding pharmacies are increasingly exploring alternative delivery methods and pricing models to improve accessibility, meanwhile, major pharmaceutical companies continue investing heavily in next- generation oral GLP-1 therapies, creating a highly competitive landscape.

Industry impact

The dispute underscores the tension between innovation, intellectual- property protection, and patient affordability, pharmaceutical manufacturers seek to protect years of research in clinical investment, while telehealth companies aim to expand access through lower- cost alternatives, regulatory agencies are expected to play a critical role in returning how compounded obesity medicines can be marketed and distributed in the future.

Market Outlook

The global obesity- treatment market is projected to exceed $ 100 billion by the end of the decade, driven by rising obesity rates and strong demand for convenient oral therapies, competition among companies such as Nova Nordisk and Eliu Lilly, and Hims & Hers Health is expected to accelerate innovation, expand patient access, and intensify pricing competition across the GLP-1 segment